Shares of uniQure fell as much as 66% on November 3, 2025, after the drug developer said the FDA deemed the clinical data for its experimental gene-therapy for Huntington’s disease insufficient. One market analyst called the news “surprising,” and said it marked a “considerable shift from prior communications” between the regulator and the company.
Contact our attorneys for a no-cost case evaluation.